Poland
· Delayed Price · Currency is PLN Molecure Statistics
Total Valuation
Molecure has a market cap or net worth of PLN 232.34 million. The enterprise value is 186.59 million.
| Market Cap | 232.34M |
| Enterprise Value | 186.59M |
Important Dates
The last earnings date was Friday, September 6, 2024.
| Earnings Date | Sep 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Molecure has 16.84 million shares outstanding. The number of shares has increased by 24.88% in one year.
| Shares Outstanding | 16.84M |
| Shares Change (YoY) | +24.88% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 4.12% |
| Owned by Institutions (%) | 15.02% |
| Float | 10.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 125.16 |
| PB Ratio | 2.47 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.36 |
| EV / Sales | 96.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.97 |
Financial Position
The company has a current ratio of 5.79, with a Debt / Equity ratio of 7.03.
| Current Ratio | 5.79 |
| Quick Ratio | 5.63 |
| Debt / Equity | 7.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.39 |
| Interest Coverage | -791.82 |
Financial Efficiency
Return on equity (ROE) is -26.99% and return on invested capital (ROIC) is -17.70%.
| Return on Equity (ROE) | -26.99% |
| Return on Assets (ROA) | -16.87% |
| Return on Capital (ROIC) | -17.70% |
| Revenue Per Employee | 17,257 |
| Profits Per Employee | -261,832 |
| Employee Count | 111 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.03% in the last 52 weeks. The beta is 2.21, so Molecure's price volatility has been higher than the market average.
| Beta (5Y) | 2.21 |
| 52-Week Price Change | -22.03% |
| 50-Day Moving Average | 14.73 |
| 200-Day Moving Average | 16.40 |
| Relative Strength Index (RSI) | 38.61 |
| Average Volume (20 Days) | 8,015 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Molecure had revenue of PLN 1.93 million and -29.33 million in losses. Loss per share was -1.68.
| Revenue | 1.93M |
| Gross Profit | -1.76M |
| Operating Income | -32.54M |
| Pretax Income | -29.33M |
| Net Income | -29.33M |
| EBITDA | -30.97M |
| EBIT | -32.54M |
| Loss Per Share | -1.68 |
Balance Sheet
The company has 52.37 million in cash and 6.62 million in debt, giving a net cash position of 45.75 million or 2.72 per share.
| Cash & Cash Equivalents | 52.37M |
| Total Debt | 6.62M |
| Net Cash | 45.75M |
| Net Cash Per Share | 2.72 |
| Equity (Book Value) | 94.09M |
| Book Value Per Share | 5.59 |
| Working Capital | 45.09M |
Cash Flow
In the last 12 months, operating cash flow was -16.42 million and capital expenditures -586,890, giving a free cash flow of -17.01 million.
| Operating Cash Flow | -16.42M |
| Capital Expenditures | -586,890 |
| Free Cash Flow | -17.01M |
| FCF Per Share | -1.01 |
Margins
| Gross Margin | -91.16% |
| Operating Margin | -1,683.45% |
| Pretax Margin | -1,517.22% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -879.94% |
Dividends & Yields
Molecure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.88% |
| Shareholder Yield | -24.88% |
| Earnings Yield | -12.17% |
| FCF Yield | -7.32% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Molecure has an Altman Z-Score of 11.66.
| Altman Z-Score | 11.66 |
| Piotroski F-Score | n/a |